Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Invesco Ltd. (IVZ) - free report >>
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Invesco Ltd. (IVZ) - free report >>
Image: Bigstock
Best Momentum Stocks to Buy for July 15th
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 15th:
Futu Holdings Limited (FUTU - Free Report) : This online brokerage and wealth management platform has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 7.4% over the last 60 days.
Futu Holdings Limited Sponsored ADR Price and Consensus
Futu Holdings Limited Sponsored ADR price-consensus-chart | Futu Holdings Limited Sponsored ADR Quote
Futu’ shares gained 82.5% over the last three months compared with the S&P 500’s advance of 18.7%. The company possesses a Momentum Score of A.
Futu Holdings Limited Sponsored ADR Price
Futu Holdings Limited Sponsored ADR price | Futu Holdings Limited Sponsored ADR Quote
Invesco Ltd. (IVZ - Free Report) : This publicly owned investment manager has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 7.1% over the last 60 days.
Invesco Ltd. Price and Consensus
Invesco Ltd. price-consensus-chart | Invesco Ltd. Quote
Invesco’s shares gained 37.2% over the last three months compared with the S&P 500’s advance of 18.7%. The company possesses a Momentum Score of A.
Invesco Ltd. Price
Invesco Ltd. price | Invesco Ltd. Quote
RAPT Therapeutics, Inc. (RAPT - Free Report) : This clinical-stage immunology-based biopharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 72.1% over the last 60 days.
Rapt Therapeutics Price and Consensus
Rapt Therapeutics price-consensus-chart | Rapt Therapeutics Quote
RAPT Therapeutics’ shares gained 36.1% over the last three months compared with the S&P 500’s advance of 18.7%. The company possesses a Momentum Score of A.
Rapt Therapeutics Price
Rapt Therapeutics price | Rapt Therapeutics Quote
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.